Navigation Links
WPI Biomedical Technology in final 4 of international business plan contest
Date:2/27/2013

Worcester, Mass. A start-up commercializing biomedical technology developed at Worcester Polytechnic Institute (WPI) for wound healing and tissue regeneration is one of four finalists in this year's Association of University Technology Managers (AUTM) international business plan contest.

VitaThreads launched in 2012 to commercialize the pioneering research of George Pins and Glenn Gaudette, who are both associate professors of biomedical engineering at WPI. The company is developing biopolymer microthreads that can be used as therapies and as delivery vehicles for cells to treat conditions that range from common sports injuries to heart attacks. VitaThreads will present its business plan and field questions from a panel of judges on March 1 in San Antonio, Texas, at the AUTM Venture Forum, which is part of the group's 2013 annual global meeting. The winning company will receive a $10,000 cash prize.

"We are very excited about this opportunity to tell our story and present our business plan to some of the industry's top investors and business development experts," said Adam Collette, vice president of product development at VitaThreads, who will be making the presentation at AUTM. "I think it speaks highly of the technology and of the work our team has done to get the company to this point."

With over 3,000 members from 300 universities, research institutions, and business development groups, AUTM is the premier international professional organization promoting the commercialization of technologies that emerge from academic research. This year, 30 companies entered the business plan competition. After two rounds of review, four were selected as finalists.

"We were impressed by the quality of companies represented in this year's competition, and we're thrilled to provide a high-profile platform to showcase these exciting companies that are born from academic research," Stephen Susalka, assistant vice president at AUTM, said in a media release announcing the finalists. "The AUTM Annual Meeting is the largest gathering of academic technology commercialization professionals under one roof, and is a unique opportunity for venture capitalists to access the latest academic breakthroughs ripe for investment."

About the width of a human hair, the microthreads VitaThreads produces are made of collagen, fibrin, and other biologic materials. The microthreads can be braided into cable-like structures that mimic natural tissues like tendons, ligaments, and muscle fibers. First developed in Pins's lab as a potential tool for repairing torn anterior cruciate ligaments (ACL) in the knee, the microthreads were adapted by Pins and Gaudette for use as biological sutures to deliver bone marrowderived stem cells to regenerate cardiac muscle damaged during a heart attack. Other WPI labs are using the threads, seeded with varying cell types, as scaffolds for wound healing and skeletal muscle regeneration, among other purposes.

"The VitaThreads case is a great example of how WPI strives to accelerate innovation and develop ideas into products that meet important needs," said Todd Keiller, director of technology transfer at WPI and a member of AUTM.

Pins and Gaudette are co-founders of the company and serve as scientific advisors to the VitaThreads management team, which includes co-founders Collette and CEO Harry Wotton '94. The company began operations within WPI's Bioengineering Institute and has since moved to its own space within the Massachusetts Biomedical Initiatives (MBI) incubator facility at Gateway Park in Worcester. Its first clinical target is to develop a new treatment for Achilles tendon injuries.

"This is a special opportunity to put WPI and our technology on an international stage, in front of a group of people who can help bring these potential new therapies to the clinic," Pins said. "Just making the final four in this level of competition already feels like a win."

The other finalists in the competition are BioReplicon, which is developing clinical diagnostic tests based on technology from the University of Texas at Austin and Gang-Gung University; Iowa Approach, which is developing a device to treat heart arrhythmias based on technology from the University of Iowa; and Retectix, which is developing a surgical mesh product based on technology from Washington University in St. Louis.

"We are in very good company with the other finalists, and we feel honored to have made it this far," Gaudette said. "It's also interesting that all of the finalists this year are biomedical technologies. That, I think, shows the growing impact of integrating engineering and life sciences expertise to create new therapies that help people, which is precisely our mission here at WPI."


'/>"/>

Contact: Michael Cohen
mcohen@wpi.edu
508-868-4778
Worcester Polytechnic Institute
Source:Eurekalert  

Related biology news :

1. Nuisance seaweed found to produce compounds with biomedical potential
2. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
3. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
4. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
5. Top young Latin-American scientists named Pew Biomedical Fellows
6. Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
7. BGI Tech and BAB jointly develop transgenic mice platform for biomedical research
8. Reproducibility Initiative to increase the value of biomedical research
9. £30 million boost for biomedical engineering research
10. MU celebrates $5 million partnership for advancing biomedical discoveries
11. CNIO participates in the ENCODE project: A stride forward in biomedical research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
WPI Biomedical Technology in final 4 of international business plan contest
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: